Liquid Segment has the Largest Share of State of Finished Products in the Middle East & Africa Pharmaceutical Fill and Finish Outsourcing Market during 2021–2028

According to our latest study on “Middle East & Africa Pharmaceutical Fill and Finish Outsourcing Market Forecast to 2028 – COVID-19 Impact and Analysis – by State of Finished Products, and Content,” the market is projected to reach US$ 79.4 million by 2028 from US$ 60.0 million in 2021; it is expected to grow at a CAGR of 4.1% from 2021 to 2028. The report highlights trends prevailing in the market, and the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the increase in demand for biopharmaceutical drugs, growing clinical developments, and development of biologics and biosimilars. However, complex processes and high cost of production critically impacts the growth of the market.

With the onset of pandemic, the demand for contract manufacturers accelerated. For instance, GCC companies are looking to compete in contract manufacturing. For example, with around 30 pharmaceutical companies, the GCC pharmaceutical industry is still evolving and is currently dominated by Saudi Arabia accounting to 65% of the GCC pharmaceutical market share. Furthermore, Ahramonline report states that, the Egyptian Drug Authority (EDA) has activated a package of incentive measures for contract manufacturing pharmaceuticals and medical supplies for opening new markets and increase the export value of Egyptian pharmaceutical products and increase incentive for pharmaceutical investment. Moreover, four pharmaceutical companies have applied for contract manufacturing in 2019 and 2020, and 57 products have been approved for export to Sudan, Saudi Arabia, Cyprus, and Yemen.

Based on state of finished products, the liquid segment is expected to register the largest market share during the forecast period. Moreover, the same segment is estimated to register the highest CAGR during the forecast period. In 2021, the liquid segment accounted for the highest share, moreover the same segment is expected to grow at a CAGR of 6.0% in the forecast period.

Abbott, TEVA PHARMACEUTICAL INDUSTRIES LTD, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries Ltd, Piramal Enterprises Ltd., Cytovance Biologics, Thermo Fisher Scientific Inc. (Patheon N.V), and Boehringer Ingelheim International GmbH are among the leading companies in the Middle East & Africa pharmaceutical fill and finish outsourcing market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market.

The market for pharmaceutical fill and finish outsourcing market is segmented into state of finished products and content. Based on state of finished products, the Middle East & Africa pharmaceutical fill and finish outsourcing market is segmented into solids, semi-liquid and liquid. Based on content, the pharmaceutical fill and finish outsourcing market is segmented into organic substances isolated from animal origin, organic substances isolated from microorganisms, and inorganic substances. Geographically, the pharmaceutical fill and finish outsourcing market is segmented into Middle East & Africa (UAE, Saudi Arabia, South Africa, Rest of Middle East & Africa).

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com